A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

RecruitingPhase 1/2

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Who can join

Ages 12 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)

Exclusion Criteria:

* Received treatment with another RBM39 degrader
* Clinically significant gastrointestinal (GI) or GI malabsorption

About the study

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

What is being tested

REC-1245 (drug)

Sponsor: Recursion Pharmaceuticals Inc. · Participants: 170 · Started: Nov 21, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06678659

Locations in the U.S.

California	City of Hope, Duarte Sarcoma Oncology Research Center, Santa Monica
Ohio	Cleveland Clinic, Cleveland
Utah	START Mountain Region, West Valley City

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.